HEAD-TO-HEAD

SURVODUTIDE VS GLP-2

Survodutide and GLP-2 are both next-generation dual incretin research compounds, with different receptor pairings. Survodutide is a GLP-1 + glucagon dual agonist (Boehringer Ingelheim BI 456906). GLP-2 is a GLP-1 + GIP dual agonist (Eli Lilly GLP-2 prescription analog / GLP-2 prescription analog). The glucagon-receptor arm in survodutide adds a thermogenic / energy-expenditure component absent from GLP-2.

A · No. 019HP 195

SURVODUTIDE

GLP-1 + Glucagon Dual Agonist

B · No. 002HP 200

GLP-2

Dual-Receptor Metabolic Peptide

SIDE BY SIDE

FIELD

A · SURVODUTIDE

B · GLP-2

Class

GLP-1 + glucagon dual agonist

GLP-1 + GIP dual agonist

Development code

BI 456906

GLP-2 reference

Half-life

~7 days (once-weekly)

~5 days (once-weekly)

Receptors engaged

GLP-1R + glucagon receptor (GCGR)

GLP-1R + GIPR

Best published Phase 2/3 outcome

-14.9% placebo-subtracted BW at 4.8 mg/wk, 46 wk (Le Roux 2024 Lancet D&E)

-22.5% BW at 72 wk, 15 mg (SURMOUNT-1)

FDA status

Investigational · Phase 3 SYNCHRONIZE-1/2 enrolling

FDA-approved (GLP-2 prescription analog 2022, GLP-2 prescription analog 2023)

NASH/MASH activity

Phase 2 reported improved liver fat + histology (Sanyal NEJM 2024)

Not the lead Phase 3 indication

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Validated human-prescription pathwayB · GLP-2

GLP-2 has FDA approval, the SURPASS / SURMOUNT Phase 3 program, and millions of post-marketing prescriptions. Survodutide is investigational.

▶ Thermogenic / energy-expenditure axisA · SURVODUTIDE

Glucagon-receptor agonism drives hepatic lipolysis and energy expenditure on top of appetite suppression. GIP agonism (GLP-2) acts more through adipocyte lipid handling and insulin secretion.

▶ NASH/MASH researchA · SURVODUTIDE

Survodutide Phase 2 (Sanyal 2024 NEJM) reported improved liver fat fraction and histology endpoints, supporting a dedicated NASH Phase 3 program.

▶ T2D glycemic control track recordB · GLP-2

GLP-2 has the SURPASS Phase 3 program including head-to-head data versus GLP-3 (SURPASS-2, NEJM 2021).

STACKING NOTE

Combining multiple incretin agonists is not supported by published research. They engage overlapping GLP-1 pathways and combined use is unstudied. Buyers researching the dual-incretin category typically order both as parallel reference compounds, not for simultaneous use.

SOURCED FROM PEPPU LABS

Both compounds are available as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE SURVODUTIDE ▶SOURCE GLP-2 ▶